Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 40Neoplasms, Plasma Cell 13Lymphoma 12Neuroblastoma 10Leukemia, Myeloid, Acute 10Lymphoma, Large B-Cell, Diffuse 9Immunoglobulin Light-chain Amyloidosis 8Lymphoma, Non-Hodgkin 6Myelodysplastic Syndromes 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Follicular 5Uveal Melanoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Melanoma 3Lymphoma, Mantle-Cell 3Leukemia 3Amyloidosis 3Neoplasm Metastasis 2Hodgkin Disease 2Ganglioneuroblastoma 2Venentoclax 1Smoldering Multiple Myeloma 1Sarcoma, Ewing 1Sarcoma 1Retinoblastoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms by Histologic Type 1

Interventions

Melphalan 3Dexamethasone 3Bortezomib 3daratumumab 1Filgrastim 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Amyloidosis × Melphalan × Clear all
NCT01078454 2022-02-01

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

National Cancer Institute (NCI)

Phase 3 Completed
11 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01277016 2017-03-10

EMN-03

European Myeloma Network B.V.

Phase 3 Completed
110 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01998503 2013-11-29

Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis

Nanjing University School of Medicine

Phase 3 Completed
56 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡